NASDAQ:TCON

TRACON Pharmaceuticals - TCON Stock Forecast, Price & News

$1.67

-0.07 (-4.02%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.66
▼
$1.81
50-Day Range: $1.67
▼
$2.22
52-Week Range: $1.24
▼
$4.14

Volume: 109,138 shs
Average Volume: 71,136 shs
Market Capitalization: $35.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

TRACON Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 498.8% Upside
$10.00 Price Target
Short Interest: Healthy
0.65% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.78
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$86,841 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.87) to ($1.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

707th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

118th out of 171 stocks

3.5

Analyst's Opinion

Consensus Rating
TRACON Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, TRACON Pharmaceuticals has a forecasted upside of 498.8% from its current price of $1.67.
Amount of Analyst Coverage
TRACON Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.65% of the outstanding shares of TRACON Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
TRACON Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TRACON Pharmaceuticals has recently increased by 6.81%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
TRACON Pharmaceuticals does not currently pay a dividend.
Dividend Growth
TRACON Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TCON.

2.1

News and Social Media Coverage

News Sentiment
TRACON Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for TRACON Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for TCON on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TRACON Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,841.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.54% of the stock of TRACON Pharmaceuticals is held by insiders.
Percentage Held by Institutions
52.93% of the stock of TRACON Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for TRACON Pharmaceuticals are expected to decrease in the coming year, from ($0.87) to ($1.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TRACON Pharmaceuticals is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TRACON Pharmaceuticals is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TRACON Pharmaceuticals has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TRACON Pharmaceuticals (NASDAQ:TCON) Stock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

September 25, 2022 | americanbankingnews.com

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Major Shareholder Acquires $29,948.03 in Stock

September 25, 2022 | americanbankingnews.com

TRACON Pharmaceuticals (NASDAQ:TCON) Receives New Coverage from Analysts at StockNews.com

September 14, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals earns FDA fast track designation for sarcoma drug envafolimab

September 14, 2022 | seekingalpha.com

Tracon wins FDA’s fast track status for connective tissue tumor candidate

September 14, 2022 | finance.yahoo.com

TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

September 7, 2022 | finance.yahoo.com

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

September 6, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals strikes $35M debt financing facility with Runway Growth Capital

September 6, 2022 | finance.yahoo.com

TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital

August 30, 2022 | finance.yahoo.com

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

August 29, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals announces FDA approval for CTLA-4 antibody YH001 for treating sarcoma in combination with envafolimab

August 29, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals welcomes FDA approval of IND for CTLA-4 antibody YH001 for treating sarcoma in combination with envafolimab

August 29, 2022 | finance.yahoo.com

TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer

August 29, 2022 | finance.yahoo.com

TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

August 10, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals ends 2Q with strong cash runway to support key trials

August 10, 2022 | finance.yahoo.com

TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals says ENVASARC trial gets recommendation to proceed as planned

August 8, 2022 | msn.com

TRACON Seeks FDA Nod For Initial-Stage Tissue Cancer Study

August 8, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals submits new drug application for the treatment of sarcoma patients in combination with envafolimab

August 8, 2022 | finance.yahoo.com

TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

July 27, 2022 | finance.yahoo.com

TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022

July 26, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals announces milestone dosing of 36th patient in ENVASARC pivotal trial

July 26, 2022 | proactiveinvestors.com

TRACON Pharmaceuticals enrols 36th patient at ENVASARC trial triggering 4Q interim efficacy analysis

July 26, 2022 | finance.yahoo.com

TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter

June 2, 2022 | finance.yahoo.com

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 12, 2022 | seekingalpha.com

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q1 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Company Calendar

Last Earnings: 8/10/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TCON
CUSIP: N/A
CIK: 1394319
Web: www.traconpharma.com
Phone: (858) 550-0780
Fax: 858-550-0786
Employees: 19
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +498.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,670,000.00
Net Margins: N/A
Pretax Margin: -9,559.54%
Return on Equity: -338.27%
Return on Assets: -129.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.17
Quick Ratio: 1.17

Sales & Book Value

Annual Sales: $350,000.00
Price / Sales: 102.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 2.78

Miscellaneous

Outstanding Shares: 21,420,000
Free Float: 20,664,000
Market Cap: $35.77 million
Optionable: Not Optionable
Beta: 1.41

Key Executives

Dr. Charles P. Theuer M.D. (Age 58)
Ph.D., CEO, Pres & Director
Comp: $827.53k

Mr. Scott B. Brown CPA (Age 41)
M.S., Chief Financial Officer
Comp: $459.21k

Mr. Mark C. Wiggins M.B.A. (Age 66)
Chief Bus. Officer
Comp: $506.25k

Ms. Bonne Adams (Age 45)
Exec. VP of Clinical Operations

Mr. Shahe Garabedian
Sr. VP & Head of Quality Assurance

Dr. James L. Freddo (Age 67)
Chief Medical Officer

Mr. Ya Huang
Exec. Director of Statistical Programming

Dr. Brenda Marczi Pharm.D.
Pharmd Mba, Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCON Stock - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TCON shares.
View TCON analyst ratings or view top-rated stocks.
What is TRACON Pharmaceuticals' stock price forecast for 2022?: 1 brokerages have issued 1 year target prices for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 498.8% from the stock's current price.
View analysts price targets for TCON or view top-rated stocks among Wall Street analysts.
How have TCON shares performed in 2022?: TRACON Pharmaceuticals' stock was trading at $2.77 at the beginning of the year. Since then, TCON shares have decreased by 39.7% and is now trading at $1.67.
View the best growth stocks for 2022 here.
When is TRACON Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our TCON earnings forecast.
How were TRACON Pharmaceuticals' earnings last quarter?: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) posted its quarterly earnings results on Wednesday, August, 10th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.02.

What other stocks do shareholders of TRACON Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).
When did TRACON Pharmaceuticals IPO?: (TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.
What is TRACON Pharmaceuticals' stock symbol?: TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."
How do I buy shares of TRACON Pharmaceuticals?: Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is TRACON Pharmaceuticals' stock price today?: One share of TCON stock can currently be purchased for approximately $1.67.
How much money does TRACON Pharmaceuticals make?: TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $35.77 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-28,670,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.
How can I contact TRACON Pharmaceuticals?: TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.

This page (NASDAQ:TCON) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

TRACON Pharmaceuticals - TCON Stock Forecast, Price & News

TRACON Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month